

Valeant Pharmaceuticals International, Inc.  
Form 8-K  
December 02, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): December 2, 2013 (December 2, 2013)**

**Valeant Pharmaceuticals International, Inc.**  
**(Exact name of registrant as specified in its charter)**

**British Columbia, Canada**  
**(State or other jurisdiction of**

**incorporation)**

**001-14956**  
**(Commission**

**File Number)**  
**2150 St. Elzéar Blvd. West,**

**98-0448205**  
**(IRS Employer**

**Identification No.**

**Laval, Quebec**

**Canada H7L 4A8**

**(Address of principal executive offices) (Zip Code)**

**514-744-6792**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

**Redemption of Notes**

On December 2, 2013, Valeant Pharmaceuticals International, Inc. (the Company ) issued a press release announcing that Valeant Pharmaceuticals International, a wholly owned subsidiary of the Company, will redeem the remaining \$465.5 million aggregate principal amount of its outstanding 6.50% Senior Notes due 2016 and has mailed an irrevocable notice of redemption for such notes. On November 15, 2013, Valeant Pharmaceuticals International mailed an irrevocable notice of redemption for \$450 million aggregate principal amount of such notes. The press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	Press Release announcing redemption of notes, dated December 2, 2013

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS INTERNATIONAL

By: /s/ Howard B. Schiller  
Name: Howard B. Schiller  
Title: Executive Vice President and  
Chief Financial Officer

Date: December 2, 2013

**EXHIBIT INDEX**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press Release announcing redemption of notes, dated December 2, 2013